Orange Book product · Brand (NDA)
XENOVIEW
XENON XE-129 HYPERPOLARIZED
At a glance
Dec 23, 2022
Approved
Brand (NDA)
Application
Not listed
TE code
2
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 23, 2022
3 yr 6 mo ago
Today
Exclusivity ends · NCE
New chemical entity exclusivity (5 years)
Dec 23, 2027
in 1 yr 6 mo
Patent 10583205 expires
Listed drug product patent expiration.
Feb 20, 2035
in 8 yr 10 mo
Patent 11052161 expires
Listed drug product patent expiration.
Dec 29, 2035
in 9 yr 8 mo
Pharmaceutical detail
Active ingredient
XENON XE-129 HYPERPOLARIZED
Strength
N/A
Dosage form
GAS
Route
INHALATION
TE code
Not listed
Application
NDA 214375
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Marketing exclusivity (1)
- NCENew chemical entity exclusivity (5 years)
Dec 23, 2027
in 1 yr 6 mo
Listed patents (2)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10583205 | Feb 20, 2035 | in 8 yr 10 mo | Product |
| 11052161 | Dec 29, 2035 | in 9 yr 8 mo | Product |
